Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Partnerships 14
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Licensing Agreements 16
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Equity Offering 20
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc – Key Competitors 27
Xenon Pharmaceuticals Inc – Key Employees 28
Xenon Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 07, 2018: Xenon Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 30
May 08, 2018: Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 07, 2018: Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update 35
Nov 07, 2017: Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 03, 2017: Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 40
May 09, 2017: Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 08, 2017: Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update 44
Corporate Communications 46
Mar 13, 2018: Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer 46
Clinical Trials 47
Sep 06, 2018: Xenon expands ion channel neurology pipeline with addition of XEN496, a “Phase 3 Ready” potassium channel modulator for the treatment of epilepsy 47
Oct 17, 2017: Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial 49
Jun 27, 2017: Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint 50
Jun 27, 2017: Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN 51
Other Significant Developments 52
Jan 08, 2018: Xenon Pharmaceuticals Outlines Key Milestones for 2018 52
Jan 08, 2017: Xenon Pharmaceuticals Outlines Key Milestones for 2017 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc, Key Competitors 27
Xenon Pharmaceuticals Inc, Key Employees 28
Xenon Pharmaceuticals Inc, Subsidiaries 29
List of Figures
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10